Building Programs to Eradicate Toxoplasmosis Part I: Introduction and Overview

Recent Findings: Morbidity and mortality from toxoplasmosis led to programs in USA, Panama, and Colombia to facilitate understanding, treatment, prevention, and regional resources, incorporating student work.

Summary: Studies foundational for building recent, regional approaches/programs are reviewed. Introduction provides an overview/review of programs in Panamá, the United States, and other countries. High prevalence/risk of exposure led to laws mandating testing in gestation, reporting, and development of broad-based teaching materials about These were tested for efficacy as learning tools for high-school students, pregnant women, medical students, physicians, scientists, public health officials and general public. Digitized, free, smart phone application effectively taught pregnant women about toxoplasmosis prevention. Perinatal infection care programs, identifying true regional risk factors, and point-of-care gestational screening facilitate prevention and care. When implemented fully across all demographics, such programs present opportunities to save lives, sight, and cognition with considerable spillover benefits for individuals and societies.

Supplementary Information: The online version contains supplementary material available at 10.1007/s40124-022-00269-w.

Citing Articles

Novel paradigm enables accurate monthly gestational screening to prevent congenital toxoplasmosis and more.

Zhou Y, Leahy K, Grose A, Lykins J, Siddiqui M, Leong N PLoS Negl Trop Dis. 2024; 18(5):e0011335.

PMID: 38805559 PMC: 11132520. DOI: 10.1371/journal.pntd.0011335.

From O/GABA-AT, GABA, and T-263 Mutant to Conception of .

Lykins J, Moschitto M, Zhou Y, Filippova E, Le H, Tomita T iScience. 2024; 27(1):108477.

PMID: 38205261 PMC: 10776954. DOI: 10.1016/j.isci.2023.108477.

Congenital toxoplasmosis among hospitalized infants in Poland in the years 2007-2021: study based on the national hospital registry.

Rzad M, Kanecki K, Lewtak K, Gorynski P, Tyszko P, Lewandowska-Andruszuk I Sci Rep. 2023; 13(1):11060.

PMID: 37422492 PMC: 10329637. DOI: 10.1038/s41598-023-38270-y.

References

McLeod R, Mack D, Boyer K, Mets M, Roizen N, Swisher C . Phenotypes and functions of lymphocytes in congenital toxoplasmosis. J Lab Clin Med. 1990; 116(5):623-35. View

Mazumdar J, Wilson E, Masek K, Hunter C, Striepen B . Apicoplast fatty acid synthesis is essential for organelle biogenesis and parasite survival in Toxoplasma gondii. Proc Natl Acad Sci U S A. 2006; 103(35):13192-7. PMC: 1559775. DOI: 10.1073/pnas.0603391103. View

Tan T, Mui E, Cong H, Witola W, Montpetit A, Muench S . Identification of T. gondii epitopes, adjuvants, and host genetic factors that influence protection of mice and humans. Vaccine. 2010; 28(23):3977-89. PMC: 2895808. DOI: 10.1016/j.vaccine.2010.03.028. View

Koppe J, LOEWER-SIEGER D, DE ROEVER-BONNET H . Results of 20-year follow-up of congenital toxoplasmosis. Lancet. 1986; 1(8475):254-6. DOI: 10.1016/s0140-6736(86)90785-3. View

Lago E . Risk factors for congenital toxoplasmosis are not always obvious. Am J Obstet Gynecol. 2006; 194(3):907. DOI: 10.1016/j.ajog.2005.07.021. View

Swisher C, Boyer K, McLeod R . Congenital toxoplasmosis. The Toxoplasmosis Study Group. Semin Pediatr Neurol. 1994; 1(1):4-25. View

Mui E, Schiehser G, Milhous W, Hsu H, Roberts C, Kirisits M . Novel triazine JPC-2067-B inhibits Toxoplasma gondii in vitro and in vivo. PLoS Negl Trop Dis. 2008; 2(3):e190. PMC: 2254147. DOI: 10.1371/journal.pntd.0000190. View

Gomez-Marin J, Munoz-Ortiz J, Mejia-Oquendo M, Arteaga-Rivera J, Rivera-Valdivia N, Bohorquez-Granados M . High frequency of ocular toxoplasmosis in Quindío, Colombia and risk factors related to the infection. Heliyon. 2021; 7(4):e06659. PMC: 8056222. DOI: 10.1016/j.heliyon.2021.e06659. View

McLeod R, Boyer K, Karrison T, Kasza K, Swisher C, Roizen N . Outcome of treatment for congenital toxoplasmosis, 1981-2004: the National Collaborative Chicago-Based, Congenital Toxoplasmosis Study. Clin Infect Dis. 2006; 42(10):1383-94. DOI: 10.1086/501360. View

10.

Vogel N, Kirisits M, Michael E, Bach H, Hostetter M, Boyer K . Congenital toxoplasmosis transmitted from an immunologically competent mother infected before conception. Clin Infect Dis. 1996; 23(5):1055-60. DOI: 10.1093/clinids/23.5.1055. View

11.

Lykins J, Filippova E, Halavaty A, Minasov G, Zhou Y, Dubrovska I . CSGID Solves Structures and Identifies Phenotypes for Five Enzymes in . Front Cell Infect Microbiol. 2018; 8:352. PMC: 6182094. DOI: 10.3389/fcimb.2018.00352. View

12.

Wallon M, Peyron F, Cornu C, Vinault S, Abrahamowicz M, Bonithon Kopp C . Congenital toxoplasma infection: monthly prenatal screening decreases transmission rate and improves clinical outcome at age 3 years. Clin Infect Dis. 2013; 56(9):1223-31. DOI: 10.1093/cid/cit032. View

13.

Stillwaggon E, Carrier C, Sautter M, McLeod R . Maternal serologic screening to prevent congenital toxoplasmosis: a decision-analytic economic model. PLoS Negl Trop Dis. 2011; 5(9):e1333. PMC: 3181241. DOI: 10.1371/journal.pntd.0001333. View

14.

Moura L, Bahia-Oliveira L, Wada M, Jones J, Tuboi S, Carmo E . Waterborne toxoplasmosis, Brazil, from field to gene. Emerg Infect Dis. 2006; 12(2):326-9. PMC: 3373086. DOI: 10.3201/eid1202.041115. View

15.

Zuther E, Johnson J, Haselkorn R, McLeod R, Gornicki P . Growth of Toxoplasma gondii is inhibited by aryloxyphenoxypropionate herbicides targeting acetyl-CoA carboxylase. Proc Natl Acad Sci U S A. 1999; 96(23):13387-92. PMC: 23957. DOI: 10.1073/pnas.96.23.13387. View

16.

Mejia-Oquendo M, Marulanda-Ibarra E, Gomez-Marin J . Evaluation of the impact of the first evidence-based guidelines for congenital toxoplasmosis in Armenia (Quindío) Colombia: An observational retrospective analysis. Lancet Reg Health Am. 2023; 1:100010. PMC: 9904040. DOI: 10.1016/j.lana.2021.100010. View

17.

Witola W, Liu S, Montpetit A, Welti R, Hypolite M, Roth M . ALOX12 in human toxoplasmosis. Infect Immun. 2014; 82(7):2670-9. PMC: 4097613. DOI: 10.1128/IAI.01505-13. View

18.

Bela S, Dutra M, Mui E, Montpetit A, Oliveira F, Oliveira S . Impaired innate immunity in mice deficient in interleukin-1 receptor-associated kinase 4 leads to defective type 1 T cell responses, B cell expansion, and enhanced susceptibility to infection with Toxoplasma gondii. Infect Immun. 2012; 80(12):4298-308. PMC: 3497418. DOI: 10.1128/IAI.00328-12. View

19.

Contopoulos-Ioannidis D, Wheeler K, Ramirez R, Press C, Mui E, Zhou Y . Clustering of Toxoplasma gondii Infections Within Families of Congenitally Infected Infants. Clin Infect Dis. 2015; 61(12):1815-24. PMC: 4657536. DOI: 10.1093/cid/civ721. View

20.

Dando C, Schroeder E, Hunsaker L, Deck L, Royer R, Zhou X . The kinetic properties and sensitivities to inhibitors of lactate dehydrogenases (LDH1 and LDH2) from Toxoplasma gondii: comparisons with pLDH from Plasmodium falciparum. Mol Biochem Parasitol. 2001; 118(1):23-32. DOI: 10.1016/s0166-6851(01)00360-7. View